stockrow
Monday 9 November 2026
Export NGEN’s income statement to Excel — free account
NervGen Pharma Corp.
NGEN- EPS
- +192.2%
- Free cash flow
- −48.1%
Quarter to June 2026, against a year earlier
1.33
0.01
+0.76%
Follow NGEN
Alert me
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
1.32 | 1.12 |
Net Debt/EBITDA |
0.95 | 0.70 |
Debt/Assets |
0.00% | 0.04% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.44 | 0.70 |
Capex/Depreciation |
0.00 | 0.00 |
| (1,037.45%) | 0.00% | |
| (205.27%) | 0.00% | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(805.79%) | (1,136.82%) |
Average Days of Receivables |
0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.02 | 0.02 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(0.19) | (0.18) |
Cash per Share |
0.22 | 0.19 |
Shareholders Equity per Share |
0.06 | 0.03 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
0.06 | 0.03 |
Free Cash Flow |
(13.96) | (12.29) |
Working Capital |
3.93 | 1.54 |
Net Current Asset Value |
3.93 | 1.54 |
| Other line items | ||
Quick Ratio |
1.28 | 1.05 |
Depreciation/Fixed assets |
0.00 | 0.00 |
Cash ROIC |
(69.70%) | (84.42%) |
Accounts Receivable Turnover |
0.00 | — |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(0.19) | (0.18) |
Capex per Share |
0.00 | 0.00 |
Average Receivables |
0.18 | — |
Average Payables |
3.47 | — |
Average Assets |
15.42 | — |
Average Common Equity |
3.05 | — |
Columns are period end dates · fundamentals updated 2 Nov 2026